

GENETIC SIGNATURES APPOINTS NON-EXECUTIVE DIRECTOR

Genetic Signatures Limited (ASX:GSS), an Australian-based global molecular diagnostics company, is pleased to announce that Mr Stephane Chatonsky has been appointed as a new Non-Executive Director from 4 December 2023.

Mr Chatonsky has over 25 years of international experience including leadership roles in venture capital, private equity, investment banking, strategy and strategic advisory services. Mr Chatonsky has held senior executive roles with global organisations such as Lazard, McKinsey & Co, Macquarie Bank and LeapFrog Investments. In addition, he has held Non-Executive Director, Chair and advisory positions for several leading pathology, healthcare and technology companies.

“Mr Chatonsky’s experience in corporate finance, investment and commercial strategy as well as sectorial experience will assist Genetic Signatures to accelerate its global growth. This will be particularly valuable as we commence commercialisation of new products based on our proprietary **3base® EasyScreen™** testing platform in the United States,” says Dr Nick Samaras, Genetic Signatures’ Non-Executive Chairman.

In accepting the appointment Mr Chatonsky said, “I am excited to be joining the Company at this time. Genetic Signatures has clearly established itself as a Company that is developing and launching innovative new products that address unmet needs into global healthcare markets. I look forward to helping shape and guide the Company during this exciting time, particularly as it is on the cusp of delivering on its strategy of establishing a meaningful presence on the in the global molecular diagnostics market.”

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Managing Director and
Chief Executive Officer
john.melki@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.